Considerations in Formulation and Device Development for Plasma Derived Therapies

3/22/2022 09:20 - 09:50

  • What are Plasma Derived Therapies?
  • Why are Plasma Derived Therapies different from other modalities?
  • What strategies do we have to tackle high drug volumes and comprehensive administration systems?
  • Challenges of higher protein concentration
  • Strategies to maintain protein stability
  • Conclusions

Andreas Liebminger, Head of Pharmaceutical Sciences and Devices for PDT R&D , Takeda